326 Optimization of GPRC5D-targeted CAR T cells (OriCAR-017) for multiple myeloma

326 Optimization of GPRC5D-targeted CAR T cells (OriCAR-017) for multiple myeloma

Bibliographic Details
Main Authors:	Yuting Zhang, Jincai Zhou, Zhongjun Shi, Feifei Shi, Siye Chen, Chenyu Huang, Huijiao Li, Ruirong Yi, Huajing Wang, Xian-Yang Li, Xiaowen He
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

S263: PHASE I OPEN-LABEL SINGLE ARM STUDY OF GPRC5D CAR-T CELLS (ORICAR-017) IN PATIENTS WITH RELAPTSED/REFRACTORY MULTIPLE MYELOMA (POLARIS)
by: M. Zhang, et al.
Published: (2022-06-01)

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
by: Maximilian Merz, et al.
Published: (2024-12-01)

CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives
by: Jincai Zhou, et al.
Published: (2024-12-01)

Targeting GPRC5D for multiple myeloma therapy
by: Dian Zhou, et al.
Published: (2024-09-01)

Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report
by: Xiaoyuan He, et al.
Published: (2025-03-01)

Updates on CAR T cell therapy in multiple myeloma
by: Fatemeh Nasiri, et al.
Published: (2024-09-01)

CAR T-cell therapy: is it prime time in myeloma?
by: Surbhi Sidana, et al.
Published: (2019-11-01)

CAR-T Therapy in Multiple Myeloma: Looking Beyond
by: Gianluca Maiorana, et al.
Published: (2024-05-01)

CAR-T cell therapy in myeloma: hopes and hurdles
by: Jean Luc Harousseau
Published: (2023-04-01)

The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer
by: Pengfei Yan, et al.
Published: (2024-06-01)

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
by: Benedetto Bruno, et al.
Published: (2021-04-01)

REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY
by: Ulrike Bacher, et al.
Published: (2021-01-01)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
by: Maria Sjöstrand, et al.
Published: (2023-02-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
by: Paula Rodriguez-Otero, et al.
Published: (2024-02-01)

Current Status of CAR-T Cell Therapy in Multiple Myeloma
by: Juan Luis Reguera-Ortega, et al.
Published: (2021-10-01)

Recent updates on CAR T clinical trials for multiple myeloma
by: Quande Lin, et al.
Published: (2019-11-01)

Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
by: Marcin Jasiński, et al.
Published: (2021-02-01)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
by: Hongwen Li, et al.
Published: (2023-05-01)

Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China’s responses to address secondary cancer risks of CAR-T therapy
by: Ruirong Tan, et al.
Published: (2024-10-01)

Cars, cars and more cars [kasetvideo]
Published: ([197)

DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
by: Praveen Neeli, et al.
Published: (2024-10-01)

Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
by: Paula Rodriguez-Otero, et al.
Published: (2024-03-01)

1182 Bispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
by: Benjamin Doranz, et al.
Published: (2023-11-01)

Maximizing the Benefit of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma
by: Federico Simonetta
Published: (2022-10-01)

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma
by: Johannes M. Waldschmidt, et al.
Published: (2025-03-01)

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01)

Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma
by: Fernando J. Medina-Olivares, et al.
Published: (2024-07-01)

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01)

Road testing new CAR design strategies in multiple myeloma
by: Priyanka S. Rana, et al.
Published: (2022-08-01)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
by: Luis Gerardo Rodríguez-Lobato, et al.
Published: (2020-07-01)

CAR T-cell therapy in multiple myeloma: more room for improvement
by: Phaik Ju Teoh, et al.
Published: (2021-04-01)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
by: Christopher T. Su, et al.
Published: (2021-07-01)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
by: Simon Thomas, et al.
Published: (2023-06-01)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
by: Vita Golubovskaya, et al.
Published: (2021-10-01)

The research significance of concomitant use of CAR-CD138-NK and CAR-CD19-NK to target multiple myelomas
by: Songbo Zhao, et al.
Published: (2018-07-01)

circGprc5a Promoted Bladder Oncogenesis and Metastasis through Gprc5a-Targeting Peptide
by: Chaohui Gu, et al.
Published: (2018-12-01)

333 Empowering cancer immunotherapy by mesothelin-directed CAR T cells engineered to secret checkpoint inhibitors
by: Jiantao Wang, et al.
Published: (2023-11-01)

Correction: Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
Published: (2023-07-01)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
by: Kevin Pan, et al.
Published: (2022-03-01)